Amarin Corp Plc (AMRN)

[Whalatane]

Gabor ...from the previous post to BC

In addition, more intensive (i.e., potent) statin regimens have been found to have greater efficacy compared to less-intensive regimens.

The CTT meta-analysis demonstrated that 1 mmol/L (~39 mg/dL) reduction in LDL-C resulted in a 10% relative reduction in all-cause mortality and a 21% relative reduction in MVE for statins vs placebo.

Decreases in the rate of individual endpoints per 1 mmol/L LDL-C reductions were major coronary events (24%), coronary revascularization (24%), ischemic stroke (20%), and any stroke (15%).

Intensive statin (≥50% LDL-C lowering) vs less intensive (<50%) regimens further reduced LDL-C by 0.51 mmol/L (20 mg/dL) and led to another 15% relative risk reduction in MVE.

These relationships were found to be consistent for all patient subtypes studied and indicated no threshold beyond which LDL-C lowering would not provide benefit (including <2 mmol/L [~80 mg/dL]), findings consistent with other large-scale studies.
--------------------------

So from JELIS secondary to R-IT , you have lowered mean LDL by at least 80md/dl ( 2 mmol/L ) and dramatically lowered CV event rates.
I know you are going to say " Well you have lowered event rates in BOTH arms ...which is correct , but I don't think you will see the same degree of separation in the arms when EPA is added to what is to me a lower risk group ( due to intense statin therapy )

JMO
Kiwi